Market Cap 2.05B
Revenue (ttm) 123.67M
Net Income (ttm) -38.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -31.24%
Debt to Equity Ratio 0.00
Volume 1,391,600
Avg Vol 1,144,760
Day's Range N/A - N/A
Shares Out 84.48M
Stochastic %K 86%
Beta 1.56
Analysts Strong Sell
Price Target $33.17

Company Profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2643
Address:
321 Harrison Avenue, Suite 900, Boston, United States
LabPsycho
LabPsycho Jul. 2 at 2:13 PM
$GLUE @oceanbleu I expect a bit of churning here $24.60 +/- $0.80 then effortless float up to $31
0 · Reply
oceanbleu
oceanbleu Jul. 2 at 1:31 PM
$GLUE ended being a nice 40% gain on the initial suggested trade , 16.3$ entry and target 1 profit taking at 23/24.9 area. Momentum looks good on hourly time frame so it is quite likely it manages tohold above 22.8 and get through the 25.5$ last resistance pivot. If it does i have two levels of interest at 26.6 and 30$.
0 · Reply
Wemby5566
Wemby5566 Jul. 1 at 2:42 PM
$GLUE Shorts Iike LabPsycho have been getting rocked. Love it
1 · Reply
LabPsycho
LabPsycho Jul. 1 at 2:36 PM
$GLUE Hmm...was that a 538,000 share block that went through last night after market at around 4:20 at $25? !!
0 · Reply
LabPsycho
LabPsycho Jun. 30 at 3:54 PM
$GLUE Repost below of one of my molecular dynamic simulations with one of GLUE (many) molecules. I am still waiting for a call - ha!
1 · Reply
LabPsycho
LabPsycho Jun. 30 at 1:43 PM
$GLUE @OptionRunners Nice find and post. IMO, 1. Did you look at other dates and puts to determine if this might be a hedge? 2. If outright call sale those calls were possibly sold to offset cost basis of the underlying asset or; 3. Considering the high risk f total loss with options, if just a purchase, ths only makes sense if the reward potential is 400-500% suggesting the buyer thinks the stock is going to over $45 - $50.
0 · Reply
LabPsycho
LabPsycho Jun. 30 at 1:37 PM
$GLUE The almost $1 spread between the bid and ask tells me this is going much higher.
0 · Reply
albertoaguinaga
albertoaguinaga Jun. 29 at 10:46 PM
0 · Reply
oneyedjacks
oneyedjacks Jun. 29 at 10:19 PM
0 · Reply
Wemby5566
Wemby5566 Jun. 29 at 8:36 PM
$GLUE Squeeze is in. We need that data to top it off
0 · Reply
Latest News on GLUE
Monte Rosa Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Earnings release: Q1 2026


Monte Rosa Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Quarterly report: Q1 2026


Monte Rosa Therapeutics Slides: Corporate presentation

May 6, 2026, 7:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Slides: Corporate presentation


Monte Rosa Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Proxy statement: Proxy filing


Monte Rosa Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Monte Rosa Therapeutics Proxy statement: Proxy filing


Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M

2026-03-17T15:05:52.000Z - 3 months ago

Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M


Monte Rosa Therapeutics Annual report: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Monte Rosa Therapeutics Annual report: Q4 2025


Monte Rosa Therapeutics Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Monte Rosa Therapeutics Earnings release: Q4 2025


Monte Rosa Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 3 months ago

Monte Rosa Therapeutics Slides: Corporate presentation


Monte Rosa Therapeutics files automatic mixed securities shelf

2026-02-11T21:40:21.000Z - 5 months ago

Monte Rosa Therapeutics files automatic mixed securities shelf


Monte Rosa Therapeutics announces $200M common stock offering

2026-01-07T21:05:48.000Z - 6 months ago

Monte Rosa Therapeutics announces $200M common stock offering


Monte Rosa Therapeutics Transcript: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Transcript: Study Result


Monte Rosa Therapeutics Press release: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Press release: Study Result


Monte Rosa Therapeutics Slides: Study Result

Jan 7, 2026, 8:00 AM EST - 6 months ago

Monte Rosa Therapeutics Slides: Study Result


Monte Rosa Therapeutics announces Phase 1 data of MRT-8102

2026-01-07T12:10:51.000Z - 6 months ago

Monte Rosa Therapeutics announces Phase 1 data of MRT-8102


Monte Rosa Therapeutics Transcript: Study Result

Dec 16, 2025, 8:00 AM EST - 7 months ago

Monte Rosa Therapeutics Transcript: Study Result


Monte Rosa Therapeutics Press release: Study Result

Dec 16, 2025, 8:00 AM EST - 7 months ago

Monte Rosa Therapeutics Press release: Study Result


Monte Rosa Therapeutics Slides: Study Result

Dec 16, 2025, 8:00 AM EST - 7 months ago

Monte Rosa Therapeutics Slides: Study Result


Monte Rosa Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Monte Rosa Therapeutics Earnings release: Q3 2025


Monte Rosa Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Monte Rosa Therapeutics Quarterly report: Q3 2025


Monte Rosa Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Monte Rosa Therapeutics Earnings release: Q2 2025


Monte Rosa Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 11 months ago

Monte Rosa Therapeutics Quarterly report: Q2 2025


Monte Rosa Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings release: Q1 2025


Monte Rosa Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Quarterly report: Q1 2025


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings Call Transcript: Q4 2024


Monte Rosa Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Annual report: Q4 2024


Monte Rosa Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Earnings release: Q4 2024


Monte Rosa Therapeutics Slides: Q4 2024

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Slides: Q4 2024


Monte Rosa Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics Quarterly report: Q3 2024


Monte Rosa Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Monte Rosa Therapeutics Earnings release: Q3 2024


This Biotech Stock Has Doubled Its Value Today—Here's Why

Oct 28, 2024, 3:06 PM EDT - 1 year ago

This Biotech Stock Has Doubled Its Value Today—Here's Why


Monte Rosa Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Quarterly report: Q2 2024


Monte Rosa Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 9:30 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q2 2024


Monte Rosa Therapeutics Announces Leadership Team Promotions

May 30, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Announces Leadership Team Promotions


Monte Rosa Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Quarterly report: Q1 2024


Monte Rosa Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q1 2024


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Proxy statement: Proxy Filing


Monte Rosa Therapeutics Earnings release: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Earnings release: Q4 2023


Monte Rosa Therapeutics Annual report: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Monte Rosa Therapeutics Annual report: Q4 2023


LabPsycho
LabPsycho Jul. 2 at 2:13 PM
$GLUE @oceanbleu I expect a bit of churning here $24.60 +/- $0.80 then effortless float up to $31
0 · Reply
oceanbleu
oceanbleu Jul. 2 at 1:31 PM
$GLUE ended being a nice 40% gain on the initial suggested trade , 16.3$ entry and target 1 profit taking at 23/24.9 area. Momentum looks good on hourly time frame so it is quite likely it manages tohold above 22.8 and get through the 25.5$ last resistance pivot. If it does i have two levels of interest at 26.6 and 30$.
0 · Reply
Wemby5566
Wemby5566 Jul. 1 at 2:42 PM
$GLUE Shorts Iike LabPsycho have been getting rocked. Love it
1 · Reply
LabPsycho
LabPsycho Jul. 1 at 2:36 PM
$GLUE Hmm...was that a 538,000 share block that went through last night after market at around 4:20 at $25? !!
0 · Reply
LabPsycho
LabPsycho Jun. 30 at 3:54 PM
$GLUE Repost below of one of my molecular dynamic simulations with one of GLUE (many) molecules. I am still waiting for a call - ha!
1 · Reply
LabPsycho
LabPsycho Jun. 30 at 1:43 PM
$GLUE @OptionRunners Nice find and post. IMO, 1. Did you look at other dates and puts to determine if this might be a hedge? 2. If outright call sale those calls were possibly sold to offset cost basis of the underlying asset or; 3. Considering the high risk f total loss with options, if just a purchase, ths only makes sense if the reward potential is 400-500% suggesting the buyer thinks the stock is going to over $45 - $50.
0 · Reply
LabPsycho
LabPsycho Jun. 30 at 1:37 PM
$GLUE The almost $1 spread between the bid and ask tells me this is going much higher.
0 · Reply
albertoaguinaga
albertoaguinaga Jun. 29 at 10:46 PM
0 · Reply
oneyedjacks
oneyedjacks Jun. 29 at 10:19 PM
0 · Reply
Wemby5566
Wemby5566 Jun. 29 at 8:36 PM
$GLUE Squeeze is in. We need that data to top it off
0 · Reply
Wemby5566
Wemby5566 Jun. 29 at 7:53 PM
$GLUE So embarrassing
0 · Reply
LabPsycho
LabPsycho Jun. 29 at 7:27 PM
$GLUE Exibit A;, post below: Baby steps movement up in price the past couple of weeks have transitionedinto strides. IMO, Roche recent PARTIAL partnership with NRIX - another protein degrader company - with a staggering $700 million upfront for one of their drugs sets a new benchmark / floor in what it will cost / big pharma must pay to play with leading degrader biotech companies. GLUE has many experts in molecular glue degrader (MGD) chemistry, artificial intelligence (AI), structural biology, and proteomics - just check out their Nature and Science papers for supporting evidence.
1 · Reply
OptionRunners
OptionRunners Jun. 29 at 7:22 PM
$GLUE $1.5M call buyer, data expected in 2H
2 · Reply
Wemby5566
Wemby5566 Jun. 29 at 4:29 PM
$GLUE Now you’re saying $32. Cmon dude we don’t forget
0 · Reply
LabPsycho
LabPsycho Jun. 29 at 2:32 PM
$GLUE IMO, This thing has is only been crawling back up but it looks to me like once it gets to about 24 I expect it to make effortless strides to over $32. Just like that - POOF!
1 · Reply
MuchMillions
MuchMillions Jun. 26 at 11:33 PM
$GLUE the short squeeze here will be epic
3 · Reply
LabPsycho
LabPsycho Jun. 26 at 9:52 PM
$GLUE Looks like a 2.9 million share trade went through at 4pm. Several other protein degrader / molecular glue companies also had huge trade at 4pm ($ERAS $TNGX ). Money appears to be flowing into XBI. And select biotech buying accelerated maybe by 500 billion $$ freed up with recent sell off chip and A.I. sector? Considering this, I think GLUE is going to blow past this year's high of $25 very soon. Furthermore, in addition, I think $NRIX recent $700 million dollar upfront deal with Roche just massively raised the ticket price for any big pharma wanting to partner with leading protein degrader / molecular glue companies.
1 · Reply
LabPsycho
LabPsycho Jun. 26 at 2:26 PM
$GLUE Some ANTICIPATED UPCOMING MILESTONES AND DEVELOPMENT PRIORITIES Immunology and Inflammation programs -- Readout of MRT-8102 GFORCE-1 study in subjects with elevated CVD risk H2 2026. -- Initiate multiple Phase 2 studies of MRT-8102, in elevated atherosclerotic risk patients in H2 2026, in gout flare patients in 2026 -Q1 2027 -- Submit an IND application for a 2nd-generation NEK7-directed MGD in H2 2026. -- Monte Rosa expects its collaborator, Novartis, to initiate multiple Phase 2 studies of VAV1-directed MGD MRT-6160 in immune-mediated diseases in 2026. Oncology programs -- Initiate the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC in Q3 2026. -- Submit an IND application for a cyclin E1-directed MGD in H2 2026.
1 · Reply
LabPsycho
LabPsycho Jun. 25 at 7:57 PM
$GLUE @oneyedjacks GLUE getting two publications in two of the highest impact scientific journals on the planet (Science and Nature, see links below) certainly lends strong credibility to your claim. https://www.science.org/stoken/author-tokens/ST-2724/full https://www.nature.com/articles/s41594-025-01738-8
0 · Reply
LabPsycho
LabPsycho Jun. 25 at 7:33 PM
$GLUE @oceanbleu I appreciate your analysis from a different perspective. A concern I have - just looking at the chart - is GLUE has gone from 4 to 20 in 9 months, so there is room below, but a lot, I mean a LOT of positive developments have happened since then.
0 · Reply
LabPsycho
LabPsycho Jun. 25 at 4:39 PM
$GLUE @oceanbleu Yes, you had a very good analysis and call on GLUE. A couple months ago I posted my predicted range for GLUE this year to be between 10 an $30. I dont know if the low since that post of $14.90 is it, but I also now think the $30 range might be a bit too low after the NRIX deal with Roche for $700 million.
2 · Reply
LabPsycho
LabPsycho Jun. 25 at 4:36 PM
$GLUE IMO, GLUE has way more going on than NRIX (another great protein degrader company) and in much larger markets than the drug Roche just paid $700 million (upfront!) to NRIX for (just part!) of their BTK degrader bexobrutideg. I am thinking any potential future payments from Novartis to GLUE are going to have to be 5-10X the hundreds of millions of $$$ Novartis previously dealt GLUE.
1 · Reply